ArticleAmerican journal of translational research2026
Pregabalin plus celecoxib for knee osteoarthritis: impact on pain, knee function recovery, and inflammatory biomarkers.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFocusing on knee osteoarthritis (KOA) patients, we explore the impact of pregabalin plus celecoxib on patients' pain, knee function recovery, and inflammatory biomarkers. This was a retrospective study.
methodsFirstly, 116 KOA patients were selected and grouped into a control group (n=55) receiving celecoxib and a research group (n=61) receiving pregabalin+celecoxib. Comparative inter-group analyses covered curative effects, Visual Analogue Scale (VAS), American Knee Society Knee Score (AKSS), serum inflammatory biomarkers, Pittsburgh Sleep Quality Index (PSQI), and adverse events. Subsequently, we explored therapeutic response-associated determinants.
resultsThe data indicated higher overall efficacy in the research group versus the control group. Pregabalin+celecoxib therapy also led to greater reductions in VAS scores, inflammatory biomarker levels, and each PSQI domain score than celecoxib alone, together with a more pronounced increase in AKSS scores across all dimensions. Similar total adverse events were found between the treatments. Finally, tumor necrosis factor (TNF)-α and treatment modality were factors independently influencing curative efficacy.
conclusionPregabalin+celecoxib therapy is definitely effective for KOA treatment. High TNF-α (≥110 μg/L) and sole celecoxib use increase the risk of ineffective treatment in KOA patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.